Compare ALEX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALEX | ARDX |
|---|---|---|
| Founded | 1870 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | ALEX | ARDX |
|---|---|---|
| Price | $20.73 | $7.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $21.00 | $12.95 |
| AVG Volume (30 Days) | 619.3K | ★ 6.6M |
| Earning Date | 02-26-2026 | 02-19-2026 |
| Dividend Yield | ★ 6.76% | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | $226,062,000.00 | ★ $398,234,000.00 |
| Revenue This Year | N/A | $22.65 |
| Revenue Next Year | $2.12 | $31.33 |
| P/E Ratio | $20.52 | ★ N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $15.07 | $3.21 |
| 52 Week High | $21.03 | $8.40 |
| Indicator | ALEX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 69.00 | 64.53 |
| Support Level | $20.68 | $7.55 |
| Resistance Level | $20.80 | $8.40 |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 34.21 | 80.43 |
Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.